Ann: OncoSil Investor Update, page-17

Hyper, so after the update the market dumped the stock. It’s been a long terrible hold this stock. No question. No scale revenues coming anytime soon as reimbursers in Europe do not accept the single arm PanCo study. Need to do a comparative study. So for the time being only private payer market for sales.

I think if there is to be a rerate it will be the FDA approval for bile duct. Oncosil can then get reimbursement for this. It’s a big if they can get FDA approval but if they do then that will lead to some solid gains IMO.

Approval from the TGA would also be very good if they can get it.

What do others think?